机构：[a]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical Universtiy, Guangzhou, Guangdong, China[b]Department of Dermatovenereology, Foshan Women and Children Hospital, Guangzhou, Guangdong, China[c]Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China[d]Department of Gynecology, The First People’s Hospital of Huizhou City, Huizhou, Guangdong, China[e]Department of Gynecology Oncology, The Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China[f]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical Universtiy, Guangzhou, China[g]Southern Medical Universtiy, Guangzhou, China[h]Department of Gynecology Oncology, The Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
LGR4 expression in serous ovarian cancer paraffin-embedded tissues and fresh tissues were investigated, and its expression associated with clinicopathological parameters and prognosis in serous ovarian cancer was explored.
From Dec, 2009 to Jan, 2020, 122 paraffin-embedded serous ovarian cancer patients and 41 paired paratumor tissues who were both diagnosed and operated at the memorial hospital of Sun Yat-sen University and Integrated Hospital of Traditional Chinese Medicine, Southern Medical University were selected in this research, respectively, and all of these tissues were performed by immunohistochemistry (IHC) with a polyclonal antibody for LGR4. Meanwhile, from Aug, 2013 to Mar, 2019, 15 cases of serous ovarian cancer fresh tissues and 15 cases of paratumor fresh tissues who were operated at Integrated Hospital of Traditional Chinese Medicine, Southern Medical University were performed with Quantitative Real-time PCR to detect the mRNA expression of LGR4, respectively.
LGR4 expression was much higher both in paraffin-embedded and fresh cancer tissues than that in paratumor tissues, respectively, and its expression was associated with recurrence free survival and overall survival in serous ovarian cancer patients. Moreover, in a multivariate model LGR4 was an indeed independent predictor of poor survival in serous ovarian cancer patients.
LGR4 is upregulated in serous ovarian cancer, and LGR4 is an indeed useful independent prognostic predictor in serous ovarian cancer, and it may provide important clinical value of serous ovarian cancer.
基金：
This work was supported by the Nature science fund of Guangdong Province (No. 2016A030313536), the Guangdong Provincial Medical Research Fund (No.A2019096), the President Funds of Integrated Hospital of Traditional Chinese Medicine, Southern Medical University (No. 1201902001; No. 1201901002).
第一作者机构：[a]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical Universtiy, Guangzhou, Guangdong, China
共同第一作者：
通讯作者：
通讯机构：[f]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical Universtiy, Guangzhou, China[g]Southern Medical Universtiy, Guangzhou, China[h]Department of Gynecology Oncology, The Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China[*1]Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical Universtiy, 13 Shiliugang ST, Guangzhou 510315, China[*2]Department of Gynecology Oncology, The Cancer Hospital of Guangzhou Medical University, Guangzhou 510000, Guangdong, China.[*3]Department of Gynecology Oncology, The Cancer Hospital of Guangzhou Medical University, Guangzhou 510000, Guangdong, China
推荐引用方式(GB/T 7714)：
Zhaoyang Zeng,Na Ji,Juanjuan Yi,et al.LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer.[J].CANCER BIOMARKERS.2020,28(1):65-72.doi:10.3233/CBM-191145.
APA：
Zhaoyang Zeng,Na Ji,Juanjuan Yi,Jin Lv,Jianhuan Yuan...&Xin Feng.(2020).LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer..CANCER BIOMARKERS,28,(1)
MLA：
Zhaoyang Zeng,et al."LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer.".CANCER BIOMARKERS 28..1(2020):65-72
